Monday January 14, 9:16 am Eastern Time
Press Release
SOURCE: Genzyme Molecular Oncology
Genzyme Molecular Oncology Expands Antiangiogenesis Focus With Appointment of Teicher
FRAMINGHAM, Mass., Jan. 14 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO - news) today announced further growth of its antiangiogenesis program by hiring a preeminent cancer research scientist to lead its continued development.
Beverly A. Teicher, Ph.D., will assume responsibility for directing Genzyme Molecular Oncology's research efforts within its newly formed partnership with Kirin Brewery Co., Ltd. of Japan. This collaboration was announced last fall and centers around the development and commercialization of fully human monoclonal antibodies. These antibody products are intended for use as therapies in the areas of antiangiogenesis and vascular targeted cancer drug delivery. Teicher will lead the project for Genzyme Molecular Oncology, and also design and guide its research efforts to validate its proprietary tumor endothelial markers as targets for small molecule therapeutics. Additionally, Teicher will be instrumental in helping to develop additional partnerships in antiangiogenesis.
Teicher joins Genzyme Molecular Oncology following tenures as a cancer researcher with Lilly Research Laboratories, the Dana-Farber Cancer Institute, Harvard Medical School and Massachusetts Institute of Technology. She begins her work with Genzyme Molecular Oncology this month.
``Beverly is an excellent addition to our team of scientists,'' stated Gail Maderis, president of Genzyme Molecular Oncology. ``With our recently formed Kirin partnership around the development and commercialization of antibodies, we're poised to significantly expand our antiangiogenesis program. Beverly's extensive expertise in pre-clinical cancer research will be very beneficial in taking this program to a new, exciting level.''
Teicher serves on the editorial boards of five major journals including Clinical Cancer Research and the International Journal of Oncology. She has served as a reviewer for more than twenty journals including Cancer, Journal of Clinical Oncology, Journal of the National Cancer Institute, and Science. She has developed technology resulting in more than 20 issued and pending patents, and has had more than 270 articles, 40 book chapters, and 12 books and monographs published. She is currently the editor of the Cancer Drug Development series being published by Humana Press, and has previously edited four books.
Teicher is a graduate of Rensselaer Polytechnic Institute, and holds advanced degrees from Johns Hopkins University. She conducted her postdoctoral training at Yale University, and has been recognized through several awards and honors. |
